Chronic	O
Hypobaric	B:C0242184
Hypoxia	I:C0242184
Induces	O
Right	O
Ventricular	I:C0162770
Hypertrophy	I:C0162770
and	O
Apoptosis	O
in	O
Rats	O
:	O
Therapeutic	O
Potential	O
of	O
Nanocurcumin	O
in	O
Improving	O
Adaptation	O
.	O

Chronic	O
Hypobaric	O
Hypoxia	I:C0242184
Induces	O
Right	B:C0162770
Ventricular	I:C0162770
Hypertrophy	I:C0162770
and	O
Apoptosis	O
in	O
Rats	O
:	O
Therapeutic	O
Potential	O
of	O
Nanocurcumin	O
in	O
Improving	O
Adaptation	O
.	O

Chronic	O
Hypobaric	O
Hypoxia	I:C0242184
Induces	O
Right	O
Ventricular	I:C0162770
Hypertrophy	I:C0162770
and	O
Apoptosis	B:C0162638
in	O
Rats	O
:	O
Therapeutic	O
Potential	O
of	O
Nanocurcumin	O
in	O
Improving	O
Adaptation	O
.	O

Chronic	O
Hypobaric	O
Hypoxia	I:C0242184
Induces	O
Right	O
Ventricular	I:C0162770
Hypertrophy	I:C0162770
and	O
Apoptosis	O
in	O
Rats	B:C0034721
:	O
Therapeutic	O
Potential	O
of	O
Nanocurcumin	O
in	O
Improving	O
Adaptation	O
.	O

Chronic	O
Hypobaric	O
Hypoxia	I:C0242184
Induces	O
Right	O
Ventricular	I:C0162770
Hypertrophy	I:C0162770
and	O
Apoptosis	O
in	O
Rats	O
:	O
Therapeutic	O
Potential	O
of	O
Nanocurcumin	B:C0010467
in	O
Improving	O
Adaptation	O
.	O

Chronic	O
Hypobaric	O
Hypoxia	I:C0242184
Induces	O
Right	O
Ventricular	I:C0162770
Hypertrophy	I:C0162770
and	O
Apoptosis	O
in	O
Rats	O
:	O
Therapeutic	O
Potential	O
of	O
Nanocurcumin	O
in	O
Improving	O
Adaptation	B:C0392673
.	O

Chronic	O
hypobaric	B:C0242184
hypoxia	I:C0242184
induces	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
and	O
apoptosis	O
in	O
rats	O
:	O
therapeutic	O
potential	O
of	O
nanocurcumin	O
in	O
improving	O
adaptation	O
.	O

Chronic	O
hypobaric	O
hypoxia	I:C0242184
induces	O
right	B:C0162770
ventricular	I:C0162770
hypertrophy	I:C0162770
and	O
apoptosis	O
in	O
rats	O
:	O
therapeutic	O
potential	O
of	O
nanocurcumin	O
in	O
improving	O
adaptation	O
.	O

Chronic	O
hypobaric	O
hypoxia	I:C0242184
induces	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
and	O
apoptosis	B:C0162638
in	O
rats	O
:	O
therapeutic	O
potential	O
of	O
nanocurcumin	O
in	O
improving	O
adaptation	O
.	O

Chronic	O
hypobaric	O
hypoxia	I:C0242184
induces	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
and	O
apoptosis	O
in	O
rats	B:C0034721
:	O
therapeutic	O
potential	O
of	O
nanocurcumin	O
in	O
improving	O
adaptation	O
.	O

Chronic	O
hypobaric	O
hypoxia	I:C0242184
induces	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
and	O
apoptosis	O
in	O
rats	O
:	O
therapeutic	O
potential	O
of	O
nanocurcumin	B:C0010467
in	O
improving	O
adaptation	O
.	O

Chronic	O
hypobaric	O
hypoxia	I:C0242184
induces	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
and	O
apoptosis	O
in	O
rats	O
:	O
therapeutic	O
potential	O
of	O
nanocurcumin	O
in	O
improving	O
adaptation	B:C0392673
.	O

17:342-352	O
,	O
2016	O
.-	O
a	O
sustained	O
work	O
load	O
on	O
the	O
right	B:C0225808
heart	I:C0225808
on	O
ascent	O
to	O
high	O
altitudes	O
promotes	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
(	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
)	O
,	O
which	O
eventually	O
undergoes	O
decompensation	O
and	O
promotes	O
pathological	O
damage	I:C0016663
.	O

17:342-352	O
,	O
2016	O
.-	O
a	O
sustained	O
work	O
load	O
on	O
the	O
right	O
heart	I:C0225808
on	O
ascent	O
to	O
high	O
altitudes	O
promotes	O
right	B:C0162770
ventricular	I:C0162770
hypertrophy	I:C0162770
(	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
)	O
,	O
which	O
eventually	O
undergoes	O
decompensation	O
and	O
promotes	O
pathological	O
damage	I:C0016663
.	O

17:342-352	O
,	O
2016	O
.-	O
a	O
sustained	O
work	O
load	O
on	O
the	O
right	O
heart	I:C0225808
on	O
ascent	O
to	O
high	O
altitudes	O
promotes	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
(	O
right	B:C0162770
ventricular	I:C0162770
hypertrophy	I:C0162770
)	O
,	O
which	O
eventually	O
undergoes	O
decompensation	O
and	O
promotes	O
pathological	O
damage	I:C0016663
.	O

17:342-352	O
,	O
2016	O
.-	O
a	O
sustained	O
work	O
load	O
on	O
the	O
right	O
heart	I:C0225808
on	O
ascent	O
to	O
high	O
altitudes	O
promotes	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
(	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
)	O
,	O
which	O
eventually	O
undergoes	O
decompensation	B:C0231187
and	O
promotes	O
pathological	O
damage	I:C0016663
.	O

17:342-352	O
,	O
2016	O
.-	O
a	O
sustained	O
work	O
load	O
on	O
the	O
right	O
heart	I:C0225808
on	O
ascent	O
to	O
high	O
altitudes	O
promotes	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
(	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
)	O
,	O
which	O
eventually	O
undergoes	O
decompensation	O
and	O
promotes	O
pathological	B:C0016663
damage	I:C0016663
.	O

Curcumin	B:C0010467
is	O
a	O
natural	O
antioxidant	O
and	O
antihypertrophic	O
agent	I:C1254351
,	O
but	O
it	O
has	O
poor	O
biostability	O
.	O

Curcumin	O
is	O
a	O
natural	O
antioxidant	B:C0003402
and	O
antihypertrophic	O
agent	I:C1254351
,	O
but	O
it	O
has	O
poor	O
biostability	O
.	O

Curcumin	O
is	O
a	O
natural	O
antioxidant	O
and	O
antihypertrophic	B:C1254351
agent	I:C1254351
,	O
but	O
it	O
has	O
poor	O
biostability	O
.	O

Nanotized	O
curcumin	B:C0010467
(	O
nanocurcumin	O
)	O
has	O
emerged	O
as	O
a	O
promising	O
agent	O
with	O
improved	O
biostability	O
while	O
retaining	O
the	O
therapeutic	O
properties	O
of	O
curcumin	O
.	O

Nanotized	O
curcumin	O
(	O
nanocurcumin	B:C0010467
)	O
has	O
emerged	O
as	O
a	O
promising	O
agent	O
with	O
improved	O
biostability	O
while	O
retaining	O
the	O
therapeutic	O
properties	O
of	O
curcumin	O
.	O

Nanotized	O
curcumin	O
(	O
nanocurcumin	O
)	O
has	O
emerged	O
as	O
a	O
promising	O
agent	O
with	O
improved	O
biostability	O
while	O
retaining	O
the	O
therapeutic	O
properties	O
of	O
curcumin	B:C0010467
.	O

The	O
present	O
study	O
aimed	O
at	O
analyzing	O
the	O
therapeutic	O
properties	O
of	O
nanocurcumin	B:C0010467
in	O
ameliorating	O
cardiac	O
damage	O
due	O
to	O
chronic	O
hypobaric	O
hypoxia	I:C0242184
(	O
hypobaric	O
hypoxia	I:C0242184
)	O
-	O
induced	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
in	O
comparison	O
to	O
curcumin	O
.	O

The	O
present	O
study	O
aimed	O
at	O
analyzing	O
the	O
therapeutic	O
properties	O
of	O
nanocurcumin	O
in	O
ameliorating	O
cardiac	B:C0018787
damage	O
due	O
to	O
chronic	O
hypobaric	O
hypoxia	I:C0242184
(	O
hypobaric	O
hypoxia	I:C0242184
)	O
-	O
induced	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
in	O
comparison	O
to	O
curcumin	O
.	O

The	O
present	O
study	O
aimed	O
at	O
analyzing	O
the	O
therapeutic	O
properties	O
of	O
nanocurcumin	O
in	O
ameliorating	O
cardiac	O
damage	O
due	O
to	O
chronic	O
hypobaric	B:C0242184
hypoxia	I:C0242184
(	O
hypobaric	O
hypoxia	I:C0242184
)	O
-	O
induced	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
in	O
comparison	O
to	O
curcumin	O
.	O

The	O
present	O
study	O
aimed	O
at	O
analyzing	O
the	O
therapeutic	O
properties	O
of	O
nanocurcumin	O
in	O
ameliorating	O
cardiac	O
damage	O
due	O
to	O
chronic	O
hypobaric	O
hypoxia	I:C0242184
(	O
hypobaric	B:C0242184
hypoxia	I:C0242184
)	O
-	O
induced	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
in	O
comparison	O
to	O
curcumin	O
.	O

The	O
present	O
study	O
aimed	O
at	O
analyzing	O
the	O
therapeutic	O
properties	O
of	O
nanocurcumin	O
in	O
ameliorating	O
cardiac	O
damage	O
due	O
to	O
chronic	O
hypobaric	O
hypoxia	I:C0242184
(	O
hypobaric	O
hypoxia	I:C0242184
)	O
-	O
induced	O
right	B:C0162770
ventricular	I:C0162770
hypertrophy	I:C0162770
in	O
comparison	O
to	O
curcumin	O
.	O

The	O
present	O
study	O
aimed	O
at	O
analyzing	O
the	O
therapeutic	O
properties	O
of	O
nanocurcumin	O
in	O
ameliorating	O
cardiac	O
damage	O
due	O
to	O
chronic	O
hypobaric	O
hypoxia	I:C0242184
(	O
hypobaric	O
hypoxia	I:C0242184
)	O
-	O
induced	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
in	O
comparison	O
to	O
curcumin	B:C0010467
.	O

Sprague	B:C0034715
-	I:C0034715
Dawley	I:C0034715
rats	I:C0034715
exposed	O
to	O
hypobaric	O
hypoxia	I:C0242184
(	O
25,000	O
feet	O
,	O
effective	O
oxygen	O
fraction	O
in	O
air	O
[	O
FIO2	O
]	O
∼	O
0.08	O
,	O
temperature	O
28	O
°C	O
±	O
1°C	O
,	O
relative	O
humidity	O
55	O
%	O
±	O
2	O
%	O
for	O
3	O
,	O
7	O
,	O
14	O
,	O
and	O
21	O
days	O
)	O
developed	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
with	O
increased	O
interstitial	O
collagen	O
content	O
,	O
Fulton	O
's	I:C0918012
index	I:C0918012
,	O
and	O
cardiomyocyte	O
cross-sectional	O
area	I:C0552389
while	O
upregulating	O
atrial	O
natriuretic	I:C0034684
peptide	I:C0034684
.	O

Sprague	O
-	I:C0034715
Dawley	I:C0034715
rats	I:C0034715
exposed	O
to	O
hypobaric	B:C0242184
hypoxia	I:C0242184
(	O
25,000	O
feet	O
,	O
effective	O
oxygen	O
fraction	O
in	O
air	O
[	O
FIO2	O
]	O
∼	O
0.08	O
,	O
temperature	O
28	O
°C	O
±	O
1°C	O
,	O
relative	O
humidity	O
55	O
%	O
±	O
2	O
%	O
for	O
3	O
,	O
7	O
,	O
14	O
,	O
and	O
21	O
days	O
)	O
developed	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
with	O
increased	O
interstitial	O
collagen	O
content	O
,	O
Fulton	O
's	I:C0918012
index	I:C0918012
,	O
and	O
cardiomyocyte	O
cross-sectional	O
area	I:C0552389
while	O
upregulating	O
atrial	O
natriuretic	I:C0034684
peptide	I:C0034684
.	O

Sprague	O
-	I:C0034715
Dawley	I:C0034715
rats	I:C0034715
exposed	O
to	O
hypobaric	O
hypoxia	I:C0242184
(	O
25,000	O
feet	O
,	O
effective	O
oxygen	O
fraction	O
in	O
air	O
[	O
FIO2	O
]	O
∼	O
0.08	O
,	O
temperature	O
28	O
°C	O
±	O
1°C	O
,	O
relative	O
humidity	O
55	O
%	O
±	O
2	O
%	O
for	O
3	O
,	O
7	O
,	O
14	O
,	O
and	O
21	O
days	O
)	O
developed	O
right	B:C0162770
ventricular	I:C0162770
hypertrophy	I:C0162770
with	O
increased	O
interstitial	O
collagen	O
content	O
,	O
Fulton	O
's	I:C0918012
index	I:C0918012
,	O
and	O
cardiomyocyte	O
cross-sectional	O
area	I:C0552389
while	O
upregulating	O
atrial	O
natriuretic	I:C0034684
peptide	I:C0034684
.	O

Sprague	O
-	I:C0034715
Dawley	I:C0034715
rats	I:C0034715
exposed	O
to	O
hypobaric	O
hypoxia	I:C0242184
(	O
25,000	O
feet	O
,	O
effective	O
oxygen	O
fraction	O
in	O
air	O
[	O
FIO2	O
]	O
∼	O
0.08	O
,	O
temperature	O
28	O
°C	O
±	O
1°C	O
,	O
relative	O
humidity	O
55	O
%	O
±	O
2	O
%	O
for	O
3	O
,	O
7	O
,	O
14	O
,	O
and	O
21	O
days	O
)	O
developed	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
with	O
increased	O
interstitial	B:C0596790
collagen	O
content	O
,	O
Fulton	O
's	I:C0918012
index	I:C0918012
,	O
and	O
cardiomyocyte	O
cross-sectional	O
area	I:C0552389
while	O
upregulating	O
atrial	O
natriuretic	I:C0034684
peptide	I:C0034684
.	O

Sprague	O
-	I:C0034715
Dawley	I:C0034715
rats	I:C0034715
exposed	O
to	O
hypobaric	O
hypoxia	I:C0242184
(	O
25,000	O
feet	O
,	O
effective	O
oxygen	O
fraction	O
in	O
air	O
[	O
FIO2	O
]	O
∼	O
0.08	O
,	O
temperature	O
28	O
°C	O
±	O
1°C	O
,	O
relative	O
humidity	O
55	O
%	O
±	O
2	O
%	O
for	O
3	O
,	O
7	O
,	O
14	O
,	O
and	O
21	O
days	O
)	O
developed	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
with	O
increased	O
interstitial	O
collagen	B:C0009325
content	O
,	O
Fulton	O
's	I:C0918012
index	I:C0918012
,	O
and	O
cardiomyocyte	O
cross-sectional	O
area	I:C0552389
while	O
upregulating	O
atrial	O
natriuretic	I:C0034684
peptide	I:C0034684
.	O

Sprague	O
-	I:C0034715
Dawley	I:C0034715
rats	I:C0034715
exposed	O
to	O
hypobaric	O
hypoxia	I:C0242184
(	O
25,000	O
feet	O
,	O
effective	O
oxygen	O
fraction	O
in	O
air	O
[	O
FIO2	O
]	O
∼	O
0.08	O
,	O
temperature	O
28	O
°C	O
±	O
1°C	O
,	O
relative	O
humidity	O
55	O
%	O
±	O
2	O
%	O
for	O
3	O
,	O
7	O
,	O
14	O
,	O
and	O
21	O
days	O
)	O
developed	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
with	O
increased	O
interstitial	O
collagen	O
content	O
,	O
Fulton	B:C0918012
's	I:C0918012
index	I:C0918012
,	O
and	O
cardiomyocyte	O
cross-sectional	O
area	I:C0552389
while	O
upregulating	O
atrial	O
natriuretic	I:C0034684
peptide	I:C0034684
.	O

Sprague	O
-	I:C0034715
Dawley	I:C0034715
rats	I:C0034715
exposed	O
to	O
hypobaric	O
hypoxia	I:C0242184
(	O
25,000	O
feet	O
,	O
effective	O
oxygen	O
fraction	O
in	O
air	O
[	O
FIO2	O
]	O
∼	O
0.08	O
,	O
temperature	O
28	O
°C	O
±	O
1°C	O
,	O
relative	O
humidity	O
55	O
%	O
±	O
2	O
%	O
for	O
3	O
,	O
7	O
,	O
14	O
,	O
and	O
21	O
days	O
)	O
developed	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
with	O
increased	O
interstitial	O
collagen	O
content	O
,	O
Fulton	O
's	I:C0918012
index	I:C0918012
,	O
and	O
cardiomyocyte	B:C0225828
cross-sectional	O
area	I:C0552389
while	O
upregulating	O
atrial	O
natriuretic	I:C0034684
peptide	I:C0034684
.	O

Sprague	O
-	I:C0034715
Dawley	I:C0034715
rats	I:C0034715
exposed	O
to	O
hypobaric	O
hypoxia	I:C0242184
(	O
25,000	O
feet	O
,	O
effective	O
oxygen	O
fraction	O
in	O
air	O
[	O
FIO2	O
]	O
∼	O
0.08	O
,	O
temperature	O
28	O
°C	O
±	O
1°C	O
,	O
relative	O
humidity	O
55	O
%	O
±	O
2	O
%	O
for	O
3	O
,	O
7	O
,	O
14	O
,	O
and	O
21	O
days	O
)	O
developed	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
with	O
increased	O
interstitial	O
collagen	O
content	O
,	O
Fulton	O
's	I:C0918012
index	I:C0918012
,	O
and	O
cardiomyocyte	O
cross-sectional	B:C0552389
area	I:C0552389
while	O
upregulating	O
atrial	O
natriuretic	I:C0034684
peptide	I:C0034684
.	O

Sprague	O
-	I:C0034715
Dawley	I:C0034715
rats	I:C0034715
exposed	O
to	O
hypobaric	O
hypoxia	I:C0242184
(	O
25,000	O
feet	O
,	O
effective	O
oxygen	O
fraction	O
in	O
air	O
[	O
FIO2	O
]	O
∼	O
0.08	O
,	O
temperature	O
28	O
°C	O
±	O
1°C	O
,	O
relative	O
humidity	O
55	O
%	O
±	O
2	O
%	O
for	O
3	O
,	O
7	O
,	O
14	O
,	O
and	O
21	O
days	O
)	O
developed	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
with	O
increased	O
interstitial	O
collagen	O
content	O
,	O
Fulton	O
's	I:C0918012
index	I:C0918012
,	O
and	O
cardiomyocyte	O
cross-sectional	O
area	I:C0552389
while	O
upregulating	B:C0949479
atrial	O
natriuretic	I:C0034684
peptide	I:C0034684
.	O

Sprague	O
-	I:C0034715
Dawley	I:C0034715
rats	I:C0034715
exposed	O
to	O
hypobaric	O
hypoxia	I:C0242184
(	O
25,000	O
feet	O
,	O
effective	O
oxygen	O
fraction	O
in	O
air	O
[	O
FIO2	O
]	O
∼	O
0.08	O
,	O
temperature	O
28	O
°C	O
±	O
1°C	O
,	O
relative	O
humidity	O
55	O
%	O
±	O
2	O
%	O
for	O
3	O
,	O
7	O
,	O
14	O
,	O
and	O
21	O
days	O
)	O
developed	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
with	O
increased	O
interstitial	O
collagen	O
content	O
,	O
Fulton	O
's	I:C0918012
index	I:C0918012
,	O
and	O
cardiomyocyte	O
cross-sectional	O
area	I:C0552389
while	O
upregulating	O
atrial	B:C0034684
natriuretic	I:C0034684
peptide	I:C0034684
.	O

Tissue	B:C0010957
damage	I:C0010957
due	O
to	O
apoptotic	O
cell	I:C0162638
death	I:C0162638
was	O
evident	O
by	O
cytochrome	O
-c	I:C0010749
/	O
caspase	O
-	I:C0291573
3	I:C0291573
activation	O
and	O
TUNEL	O
assay	I:C1515232
.	O

Tissue	O
damage	I:C0010957
due	O
to	O
apoptotic	B:C0162638
cell	I:C0162638
death	I:C0162638
was	O
evident	O
by	O
cytochrome	O
-c	I:C0010749
/	O
caspase	O
-	I:C0291573
3	I:C0291573
activation	O
and	O
TUNEL	O
assay	I:C1515232
.	O

Tissue	O
damage	I:C0010957
due	O
to	O
apoptotic	O
cell	I:C0162638
death	I:C0162638
was	O
evident	O
by	O
cytochrome	B:C0010749
-c	I:C0010749
/	O
caspase	O
-	I:C0291573
3	I:C0291573
activation	O
and	O
TUNEL	O
assay	I:C1515232
.	O

Tissue	O
damage	I:C0010957
due	O
to	O
apoptotic	O
cell	I:C0162638
death	I:C0162638
was	O
evident	O
by	O
cytochrome	O
-c	I:C0010749
/	O
caspase	B:C0291573
-	I:C0291573
3	I:C0291573
activation	O
and	O
TUNEL	O
assay	I:C1515232
.	O

Tissue	O
damage	I:C0010957
due	O
to	O
apoptotic	O
cell	I:C0162638
death	I:C0162638
was	O
evident	O
by	O
cytochrome	O
-c	I:C0010749
/	O
caspase	O
-	I:C0291573
3	I:C0291573
activation	B:C0014429
and	O
TUNEL	O
assay	I:C1515232
.	O

Tissue	O
damage	I:C0010957
due	O
to	O
apoptotic	O
cell	I:C0162638
death	I:C0162638
was	O
evident	O
by	O
cytochrome	O
-c	I:C0010749
/	O
caspase	O
-	I:C0291573
3	I:C0291573
activation	O
and	O
TUNEL	B:C1515232
assay	I:C1515232
.	O

Concomitant	O
modulation	O
of	O
cyclic	B:C0018338
guanosine	I:C0018338
monophosphate	I:C0018338
(	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
)	O
/	O
cGK	O
-	I:C3494378
1	I:C3494378
,	O
calmodulin	O
-	I:C0248868
dependent	I:C0248868
protein	I:C0248868
kinase	I:C0248868
II	I:C0248868
(	O
CaMkinase	O
II	I:C0248868
)	O
,	O
and	O
intracellular	O
calcium	O
levels	I:C0428302
with	O
increased	O
free	O
radical	I:C0016693
-	O
induced	O
damage	O
and	O
lipid	O
peroxidation	I:C0023775
further	O
contributed	O
to	O
the	O
right	O
heart	I:C0225808
pathology	O
.	O

Concomitant	O
modulation	O
of	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
(	O
cyclic	B:C0018338
guanosine	I:C0018338
monophosphate	I:C0018338
)	O
/	O
cGK	O
-	I:C3494378
1	I:C3494378
,	O
calmodulin	O
-	I:C0248868
dependent	I:C0248868
protein	I:C0248868
kinase	I:C0248868
II	I:C0248868
(	O
CaMkinase	O
II	I:C0248868
)	O
,	O
and	O
intracellular	O
calcium	O
levels	I:C0428302
with	O
increased	O
free	O
radical	I:C0016693
-	O
induced	O
damage	O
and	O
lipid	O
peroxidation	I:C0023775
further	O
contributed	O
to	O
the	O
right	O
heart	I:C0225808
pathology	O
.	O

Concomitant	O
modulation	O
of	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
(	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
)	O
/	O
cGK	B:C3494378
-	I:C3494378
1	I:C3494378
,	O
calmodulin	O
-	I:C0248868
dependent	I:C0248868
protein	I:C0248868
kinase	I:C0248868
II	I:C0248868
(	O
CaMkinase	O
II	I:C0248868
)	O
,	O
and	O
intracellular	O
calcium	O
levels	I:C0428302
with	O
increased	O
free	O
radical	I:C0016693
-	O
induced	O
damage	O
and	O
lipid	O
peroxidation	I:C0023775
further	O
contributed	O
to	O
the	O
right	O
heart	I:C0225808
pathology	O
.	O

Concomitant	O
modulation	O
of	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
(	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
)	O
/	O
cGK	O
-	I:C3494378
1	I:C3494378
,	O
calmodulin	B:C0248868
-	I:C0248868
dependent	I:C0248868
protein	I:C0248868
kinase	I:C0248868
II	I:C0248868
(	O
CaMkinase	O
II	I:C0248868
)	O
,	O
and	O
intracellular	O
calcium	O
levels	I:C0428302
with	O
increased	O
free	O
radical	I:C0016693
-	O
induced	O
damage	O
and	O
lipid	O
peroxidation	I:C0023775
further	O
contributed	O
to	O
the	O
right	O
heart	I:C0225808
pathology	O
.	O

Concomitant	O
modulation	O
of	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
(	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
)	O
/	O
cGK	O
-	I:C3494378
1	I:C3494378
,	O
calmodulin	O
-	I:C0248868
dependent	I:C0248868
protein	I:C0248868
kinase	I:C0248868
II	I:C0248868
(	O
CaMkinase	B:C0248868
II	I:C0248868
)	O
,	O
and	O
intracellular	O
calcium	O
levels	I:C0428302
with	O
increased	O
free	O
radical	I:C0016693
-	O
induced	O
damage	O
and	O
lipid	O
peroxidation	I:C0023775
further	O
contributed	O
to	O
the	O
right	O
heart	I:C0225808
pathology	O
.	O

Concomitant	O
modulation	O
of	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
(	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
)	O
/	O
cGK	O
-	I:C3494378
1	I:C3494378
,	O
calmodulin	O
-	I:C0248868
dependent	I:C0248868
protein	I:C0248868
kinase	I:C0248868
II	I:C0248868
(	O
CaMkinase	O
II	I:C0248868
)	O
,	O
and	O
intracellular	B:C0178719
calcium	O
levels	I:C0428302
with	O
increased	O
free	O
radical	I:C0016693
-	O
induced	O
damage	O
and	O
lipid	O
peroxidation	I:C0023775
further	O
contributed	O
to	O
the	O
right	O
heart	I:C0225808
pathology	O
.	O

Concomitant	O
modulation	O
of	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
(	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
)	O
/	O
cGK	O
-	I:C3494378
1	I:C3494378
,	O
calmodulin	O
-	I:C0248868
dependent	I:C0248868
protein	I:C0248868
kinase	I:C0248868
II	I:C0248868
(	O
CaMkinase	O
II	I:C0248868
)	O
,	O
and	O
intracellular	O
calcium	B:C0428302
levels	I:C0428302
with	O
increased	O
free	O
radical	I:C0016693
-	O
induced	O
damage	O
and	O
lipid	O
peroxidation	I:C0023775
further	O
contributed	O
to	O
the	O
right	O
heart	I:C0225808
pathology	O
.	O

Concomitant	O
modulation	O
of	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
(	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
)	O
/	O
cGK	O
-	I:C3494378
1	I:C3494378
,	O
calmodulin	O
-	I:C0248868
dependent	I:C0248868
protein	I:C0248868
kinase	I:C0248868
II	I:C0248868
(	O
CaMkinase	O
II	I:C0248868
)	O
,	O
and	O
intracellular	O
calcium	O
levels	I:C0428302
with	O
increased	O
free	B:C0016693
radical	I:C0016693
-	O
induced	O
damage	O
and	O
lipid	O
peroxidation	I:C0023775
further	O
contributed	O
to	O
the	O
right	O
heart	I:C0225808
pathology	O
.	O

Concomitant	O
modulation	O
of	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
(	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
)	O
/	O
cGK	O
-	I:C3494378
1	I:C3494378
,	O
calmodulin	O
-	I:C0248868
dependent	I:C0248868
protein	I:C0248868
kinase	I:C0248868
II	I:C0248868
(	O
CaMkinase	O
II	I:C0248868
)	O
,	O
and	O
intracellular	O
calcium	O
levels	I:C0428302
with	O
increased	O
free	O
radical	I:C0016693
-	O
induced	O
damage	B:C0010957
and	O
lipid	O
peroxidation	I:C0023775
further	O
contributed	O
to	O
the	O
right	O
heart	I:C0225808
pathology	O
.	O

Concomitant	O
modulation	O
of	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
(	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
)	O
/	O
cGK	O
-	I:C3494378
1	I:C3494378
,	O
calmodulin	O
-	I:C0248868
dependent	I:C0248868
protein	I:C0248868
kinase	I:C0248868
II	I:C0248868
(	O
CaMkinase	O
II	I:C0248868
)	O
,	O
and	O
intracellular	O
calcium	O
levels	I:C0428302
with	O
increased	O
free	O
radical	I:C0016693
-	O
induced	O
damage	O
and	O
lipid	B:C0023775
peroxidation	I:C0023775
further	O
contributed	O
to	O
the	O
right	O
heart	I:C0225808
pathology	O
.	O

Concomitant	O
modulation	O
of	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
(	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
)	O
/	O
cGK	O
-	I:C3494378
1	I:C3494378
,	O
calmodulin	O
-	I:C0248868
dependent	I:C0248868
protein	I:C0248868
kinase	I:C0248868
II	I:C0248868
(	O
CaMkinase	O
II	I:C0248868
)	O
,	O
and	O
intracellular	O
calcium	O
levels	I:C0428302
with	O
increased	O
free	O
radical	I:C0016693
-	O
induced	O
damage	O
and	O
lipid	O
peroxidation	I:C0023775
further	O
contributed	O
to	O
the	O
right	B:C0225808
heart	I:C0225808
pathology	O
.	O

Concomitant	O
modulation	O
of	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
(	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
)	O
/	O
cGK	O
-	I:C3494378
1	I:C3494378
,	O
calmodulin	O
-	I:C0248868
dependent	I:C0248868
protein	I:C0248868
kinase	I:C0248868
II	I:C0248868
(	O
CaMkinase	O
II	I:C0248868
)	O
,	O
and	O
intracellular	O
calcium	O
levels	I:C0428302
with	O
increased	O
free	O
radical	I:C0016693
-	O
induced	O
damage	O
and	O
lipid	O
peroxidation	I:C0023775
further	O
contributed	O
to	O
the	O
right	O
heart	I:C0225808
pathology	B:C0030664
.	O

Nanocurcumin	B:C0010467
supplementation	O
decreased	O
hypobaric	O
hypoxia	I:C0242184
-	O
induced	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
and	O
apoptosis	O
while	O
modulating	O
cardiac	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
/	O
cGK	O
-	I:C3494378
1	I:C3494378
signaling	O
,	O
and	O
maintaining	O
CaMkinase	O
II	I:C0248868
,	O
intracellular	O
calcium	O
levels	I:C0428302
and	O
redox	O
status	I:C0030012
better	O
than	O
curcumin	O
.	O

Nanocurcumin	O
supplementation	B:C1735596
decreased	O
hypobaric	O
hypoxia	I:C0242184
-	O
induced	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
and	O
apoptosis	O
while	O
modulating	O
cardiac	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
/	O
cGK	O
-	I:C3494378
1	I:C3494378
signaling	O
,	O
and	O
maintaining	O
CaMkinase	O
II	I:C0248868
,	O
intracellular	O
calcium	O
levels	I:C0428302
and	O
redox	O
status	I:C0030012
better	O
than	O
curcumin	O
.	O

Nanocurcumin	O
supplementation	O
decreased	O
hypobaric	B:C0242184
hypoxia	I:C0242184
-	O
induced	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
and	O
apoptosis	O
while	O
modulating	O
cardiac	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
/	O
cGK	O
-	I:C3494378
1	I:C3494378
signaling	O
,	O
and	O
maintaining	O
CaMkinase	O
II	I:C0248868
,	O
intracellular	O
calcium	O
levels	I:C0428302
and	O
redox	O
status	I:C0030012
better	O
than	O
curcumin	O
.	O

Nanocurcumin	O
supplementation	O
decreased	O
hypobaric	O
hypoxia	I:C0242184
-	O
induced	O
right	B:C0162770
ventricular	I:C0162770
hypertrophy	I:C0162770
and	O
apoptosis	O
while	O
modulating	O
cardiac	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
/	O
cGK	O
-	I:C3494378
1	I:C3494378
signaling	O
,	O
and	O
maintaining	O
CaMkinase	O
II	I:C0248868
,	O
intracellular	O
calcium	O
levels	I:C0428302
and	O
redox	O
status	I:C0030012
better	O
than	O
curcumin	O
.	O

Nanocurcumin	O
supplementation	O
decreased	O
hypobaric	O
hypoxia	I:C0242184
-	O
induced	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
and	O
apoptosis	B:C0162638
while	O
modulating	O
cardiac	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
/	O
cGK	O
-	I:C3494378
1	I:C3494378
signaling	O
,	O
and	O
maintaining	O
CaMkinase	O
II	I:C0248868
,	O
intracellular	O
calcium	O
levels	I:C0428302
and	O
redox	O
status	I:C0030012
better	O
than	O
curcumin	O
.	O

Nanocurcumin	O
supplementation	O
decreased	O
hypobaric	O
hypoxia	I:C0242184
-	O
induced	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
and	O
apoptosis	O
while	O
modulating	O
cardiac	B:C0018787
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
/	O
cGK	O
-	I:C3494378
1	I:C3494378
signaling	O
,	O
and	O
maintaining	O
CaMkinase	O
II	I:C0248868
,	O
intracellular	O
calcium	O
levels	I:C0428302
and	O
redox	O
status	I:C0030012
better	O
than	O
curcumin	O
.	O

Nanocurcumin	O
supplementation	O
decreased	O
hypobaric	O
hypoxia	I:C0242184
-	O
induced	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
and	O
apoptosis	O
while	O
modulating	O
cardiac	O
cyclic	B:C0018338
guanosine	I:C0018338
monophosphate	I:C0018338
/	O
cGK	O
-	I:C3494378
1	I:C3494378
signaling	O
,	O
and	O
maintaining	O
CaMkinase	O
II	I:C0248868
,	O
intracellular	O
calcium	O
levels	I:C0428302
and	O
redox	O
status	I:C0030012
better	O
than	O
curcumin	O
.	O

Nanocurcumin	O
supplementation	O
decreased	O
hypobaric	O
hypoxia	I:C0242184
-	O
induced	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
and	O
apoptosis	O
while	O
modulating	O
cardiac	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
/	O
cGK	B:C3494378
-	I:C3494378
1	I:C3494378
signaling	O
,	O
and	O
maintaining	O
CaMkinase	O
II	I:C0248868
,	O
intracellular	O
calcium	O
levels	I:C0428302
and	O
redox	O
status	I:C0030012
better	O
than	O
curcumin	O
.	O

Nanocurcumin	O
supplementation	O
decreased	O
hypobaric	O
hypoxia	I:C0242184
-	O
induced	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
and	O
apoptosis	O
while	O
modulating	O
cardiac	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
/	O
cGK	O
-	I:C3494378
1	I:C3494378
signaling	B:C0037080
,	O
and	O
maintaining	O
CaMkinase	O
II	I:C0248868
,	O
intracellular	O
calcium	O
levels	I:C0428302
and	O
redox	O
status	I:C0030012
better	O
than	O
curcumin	O
.	O

Nanocurcumin	O
supplementation	O
decreased	O
hypobaric	O
hypoxia	I:C0242184
-	O
induced	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
and	O
apoptosis	O
while	O
modulating	O
cardiac	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
/	O
cGK	O
-	I:C3494378
1	I:C3494378
signaling	O
,	O
and	O
maintaining	O
CaMkinase	B:C0248868
II	I:C0248868
,	O
intracellular	O
calcium	O
levels	I:C0428302
and	O
redox	O
status	I:C0030012
better	O
than	O
curcumin	O
.	O

Nanocurcumin	O
supplementation	O
decreased	O
hypobaric	O
hypoxia	I:C0242184
-	O
induced	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
and	O
apoptosis	O
while	O
modulating	O
cardiac	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
/	O
cGK	O
-	I:C3494378
1	I:C3494378
signaling	O
,	O
and	O
maintaining	O
CaMkinase	O
II	I:C0248868
,	O
intracellular	B:C0178719
calcium	O
levels	I:C0428302
and	O
redox	O
status	I:C0030012
better	O
than	O
curcumin	O
.	O

Nanocurcumin	O
supplementation	O
decreased	O
hypobaric	O
hypoxia	I:C0242184
-	O
induced	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
and	O
apoptosis	O
while	O
modulating	O
cardiac	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
/	O
cGK	O
-	I:C3494378
1	I:C3494378
signaling	O
,	O
and	O
maintaining	O
CaMkinase	O
II	I:C0248868
,	O
intracellular	O
calcium	B:C0428302
levels	I:C0428302
and	O
redox	O
status	I:C0030012
better	O
than	O
curcumin	O
.	O

Nanocurcumin	O
supplementation	O
decreased	O
hypobaric	O
hypoxia	I:C0242184
-	O
induced	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
and	O
apoptosis	O
while	O
modulating	O
cardiac	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
/	O
cGK	O
-	I:C3494378
1	I:C3494378
signaling	O
,	O
and	O
maintaining	O
CaMkinase	O
II	I:C0248868
,	O
intracellular	O
calcium	O
levels	I:C0428302
and	O
redox	B:C0030012
status	I:C0030012
better	O
than	O
curcumin	O
.	O

Nanocurcumin	O
supplementation	O
decreased	O
hypobaric	O
hypoxia	I:C0242184
-	O
induced	O
right	O
ventricular	I:C0162770
hypertrophy	I:C0162770
and	O
apoptosis	O
while	O
modulating	O
cardiac	O
cyclic	O
guanosine	I:C0018338
monophosphate	I:C0018338
/	O
cGK	O
-	I:C3494378
1	I:C3494378
signaling	O
,	O
and	O
maintaining	O
CaMkinase	O
II	I:C0248868
,	O
intracellular	O
calcium	O
levels	I:C0428302
and	O
redox	O
status	I:C0030012
better	O
than	O
curcumin	B:C0010467
.	O

Nanocurcumin	B:C0010467
-	O
mediated	O
antiapoptotic	O
effects	I:C0243095
might	O
have	O
benefited	O
residents	O
and	O
sojourners	O
at	O
high	O
altitude	O
in	O
preventing	O
hypoxic	O
cardiac	O
damage	O
.	O

Nanocurcumin	O
-	O
mediated	O
antiapoptotic	B:C0243095
effects	I:C0243095
might	O
have	O
benefited	O
residents	O
and	O
sojourners	O
at	O
high	O
altitude	O
in	O
preventing	O
hypoxic	O
cardiac	O
damage	O
.	O

Nanocurcumin	O
-	O
mediated	O
antiapoptotic	O
effects	I:C0243095
might	O
have	O
benefited	O
residents	O
and	O
sojourners	O
at	O
high	O
altitude	O
in	O
preventing	O
hypoxic	B:C0242184
cardiac	O
damage	O
.	O

Nanocurcumin	O
-	O
mediated	O
antiapoptotic	O
effects	I:C0243095
might	O
have	O
benefited	O
residents	O
and	O
sojourners	O
at	O
high	O
altitude	O
in	O
preventing	O
hypoxic	O
cardiac	B:C0018787
damage	O
.	O

